AssessmentExecutive Assessment
 
       
Executive Team
 

Iyabode Akinsanya-Beysolow,
MD, MPH


Andrew Angelino,
MD


Paul G. Auwaerter,
MD, MBA, FACP, FIDSA

John G. Bartlett,
MD

David Bell,
MD, MPH

Wendy Bennett,
MD, MPH


Deanna Bridge Najera,
MPAS, MS, PA-C, NCC, DFAAPA, CAQ-Psych


Todd T. Brown,
MD, Phd


Michael A. Chattergoon,
MD, PhD


Stephen Clement,
MD


Joseph Cofrancesco Jr.,
MD, MPH, FACP


Calvin J. Cohen,
MD, MSc


Sara E. Cosgrove,
MD, MS


Thomas Donner,
MD, (planning committee)


Brendan Everett,
MD, MPH


William A. Fisher II,
MD


Sandra Adamson Fryhofer,
MD, MACP, FRCP


Joel E. Gallant,
MD, MPH


Om P. Ganda,
MD


Amita Gupta,
MD, MHS


Lawrence Herman,
MPA, RPA-C, DFAAPA


Charles Hicks,
MD


Christopher Hoffmann,
MD, MPH


Michael D. Hogue,
PharmD, FAPha, FNAP


Edward H. Jasper,
MD


Rita Kalyani,
MD, MHS


Rebecca A. Kazin,
MD


Armand Krikorian,
MD, FACE


Clare J. Lee,
MD


Gregory M. Lucas,
MD, PhD


David H. Madoff,
MD, PhD


Russell L. Margolis,
MD


Kieren A. Marr,
MD


Nisa M. Maruthur,
MD, MHS


Nestoras Mathioudakis,
MD


Michael Melia,
MD


Dionissios Neofytos,
MD, MPH


Eric Nuermberger,
MD


Kathleen R. Page,
MD


Godfrey Pearlson,
MA, MBBS


Trish M. Perl,
MD, MSc


Paul A. Pham,
PharmD


Philip Raskin,
MD, FACP, FACE, CDE


Richard E. Rothman,
MD, PhD, FACEP


Catherine Salva,
MD


Paul E. Sax,
MD


Margot L. Savoy,
MD, MPH, FAAFP, FABC, CPE, CMQ


Mansur Shomali,
MD


Jay Shubrook,
DO, FACOFP, FAAFP


Aniket R. Sidhaye,
MD


Aniket R. Sidhaye,
MD


Mark S. Sulkowski,
MD


Glenn Treisman,
MD, PhD


Aimee K. Zaas,
MD, MHS


Farhad Zangeneh,
MD, FACP, FACE


 

Title: "Current Evidence and Controversies in COVID-19: Discussion on Best Practices Amid Changing Evidence”

Jointly presented by: Johns Hopkins School of Medicine and American Academy of PAs

Release Date: September 30, 2020
Expiration Date: September 30, 2021

Estimated time to complete this activity:
60 minutes. This activity has been approved for a maximum of 1.00 AMA PRA Category 1 Credit™. There are no fees or prerequisites.

Acknowledgement of Commercial Support: Supported by an independent educational grant from Merck Sharp and Dohme Corp.


Executive Team

"Optimizing Vaccination in Immunosuppressed Patients with Autoimmune and Inflammatory Disease”
This activity has been approved for a maximum of 1.00 AMA PRA Category 1 Credit™

"Current Evidence and Controversies in COVID-19: Discussion on Best Practices Amid Changing Evidence”
This activity has been approved for a maximum of 1.00 AMA PRA Category 1 Credit™

"Herpes Zoster Vaccination:What Clinicians Need to Know to Improve Vaccination Rates”
This activity has been approved for a maximum of 1.0 AMA PRA Category 1 Credits™ and 1.0 contact hours of ACPE.